Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer

Trial Profile

Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Durvalumab (Primary)
  • Indications Cervical cancer; Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advaxis
  • Most Recent Events

    • 13 Jul 2018 According to Advaxis media release, U.S. Food and Drug Administration (FDA) has lifted clinical hold on Investigational New Drug (IND) of this trial.
    • 13 Jul 2018 According to Advaxis media release, status changed from suspended to recruiting.
    • 07 Jun 2018 According to an Advaxis, Inc. media release, company plans to submit a response to the FDA shortly, and expects to receive a response from the Agency within 30 days after the submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top